Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin paclitaxel plus platinum as first-line therapy for advanced, recurrent, or metastatic cervical cancer
ChiCTR2000040042Phase 4Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Nov 2020
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nab-paclitaxel in Cervical Cancer (CC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Objective response rate. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
nab-paclitaxel
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2000040042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040042.